[Not Available].

Area of Science:

• Pharmacology
• Gastroenterology

Context:

• Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
• Gastrointestinal (GI) damage, including perforation, ulceration, and bleeding (PUBs), is a significant side effect of conventional NSAIDs.
• Selective COX-2 inhibitors were developed to reduce GI toxicity.

Purpose:

• To evaluate the efficacy and safety of selective COX-2 inhibitors compared to conventional NSAIDs.
• To assess the incidence of GI damage and cardiovascular events associated with selective COX-2 inhibitors.

Summary:

• Clinical studies indicate selective COX-2 inhibitors offer a therapeutic advantage over conventional NSAIDs, significantly reducing the incidence of GI damage (PUBs) during long-term treatment (6-9 months).
• However, PUBs are still possible with selective COX-2 inhibitors, and dyspeptic symptoms occur frequently, comparable to conventional NSAIDs.
• While initial concerns about increased cardiovascular events with some selective COX-2 inhibitors (e.g., rofecoxib) were noted, subsequent studies comparing them to placebo and other NSAIDs did not consistently confirm these findings. Celecoxib, in particular, has not shown clear thrombotic effects in clinical use.
• Preclinical data and reported cardiovascular events necessitate ongoing safety measures and further research into the thrombotic potential of COX-2 inhibitors.

Impact:

• Selective COX-2 inhibitors provide a safer alternative for patients at risk of GI complications from NSAIDs.
• The findings highlight the need for continued monitoring and research to fully understand the cardiovascular safety profile of selective COX-2 inhibitors.
• This information aids clinicians in making informed treatment decisions regarding pain management and inflammatory conditions.